Newsfeeds - Spark Newswire - Page 2

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

1 minute read

Nkarta Announces Updated Clinical Data From Phase 1 Dose Escalation Study Of NKX019; Says ‘7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response’

Today, 6:04 AM

7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate) 5 CRs achieved across all dose levels after a single cycle (3

Read More

1 minute read

Oppenheimer Maintains Outperform on Nkarta, Lowers Price Target to $36

By Benzinga Newsdesk

Today, 6:04 AM

Oppenheimer analyst Matthew Biegler maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price target from $50 to $36.

Read More

3 minute read

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies And Next Generation Commercial-Scale Manufacturing Platform At SITC 37th Annual Meeting

By Benzinga Newsdesk

Today, 6:04 AM

Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors

Read More

1 minute read

Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes

Today, 6:04 AM

Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading.

Read More

1 minute read

SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside

By Vandana Singh

Today, 6:04 AM

SVB Leerink initiated coverage on Nkarta Inc (NASDAQ:NKTX) with an Outperform rating and a price target of $30 (117% implied upside). The…

Read More

1 minute read

SVB Leerink Initiates Coverage On Nkarta with Outperform Rating, Announces Price Target of $30

By Benzinga Newsdesk

Today, 6:04 AM

SVB Leerink analyst Daina Graybosch initiates coverage on Nkarta (NASDAQ:NKTX) with a Outperform rating and announces Price Target of $30.

Read More

5 minute read

71 Biggest Movers From Yesterday

Today, 6:04 AM

Gainers

Read More

4 minute read

The Daily Biotech Pulse: Protagonist’s Ulcerative Colitis Study Disappoints, Gilead’s Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida’s Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy

By Vandana Singh

Today, 6:04 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

Read More

4 minute read

60 Biggest Movers From Yesterday

Today, 6:04 AM

Gainers

Read More

1 minute read

Raymond James Maintains Outperform on Nkarta, Raises Price Target to $32

By Benzinga Newsdesk

Today, 6:04 AM

Raymond James analyst Dane Leone maintains Nkarta (NASDAQ:NKTX) with a Outperform and raises the price target from $17 to $32.